Michael J Schuh
10.24926/iip.v10i3.2013
Innov Pharm
2019 Jul 18;10(3):10.24926/iip.v10i3.2013.
adverse drug reactions (adrs) cyp2c19 cyp2d6 comprehensive medication review (cmr) factor v leiden thrombophilia medication therapy management (mtm) pharmacogenomics (pgx) tamoxifen
CC BY-NC
https://pubmed.ncbi.nlm.nih.gov/34007571/
Case Reports
PMC8127095
34007571
Additional Utility of Pharmacogenomics (PGx) Panel Testing in a CYP2D6 Normal Metabolizer with a History of Breast Cancer
2019